Effect of Oral and Vaginal Hormonal Contraceptives on Inflammatory Blood Biomarkers
Table 3
Univariate and multivariate analysis of the blood inflammatory biomarkers by dichotomized CRP level (≤1 versus ≥3) and correlation and partial correlation between different blood inflammatory biomarkers with continuous CRP level for the selected recruited subjects.
Univariate analysis
Multivariate analysis
Blood marker
Median interquartile range
Spearman correlation with continuous CRP
Least square mean (95% CI)
Partial Spearman correlation with continuous CRP
CRP ≤ 1
CRP ≥ 3
value
value
CRP ≤ 1
CRP ≥ 3
value
value
All Subjects
MCP-1
175 [144–216]
205 [159–296]
0.08
0.16
0.16
228 (161, 296)
206 (122, 290)
0.70
0.07
0.58
IL-6
0.72 [0.45–1.18]
0.81 [0.48–1.17]
0.46
0.19
0.09
0.98 (0.71, 1.25)
1.09 (0.76, 1.42)
0.62
0.25
0.03*
sTNF-RI
842 [716–995]
875 [725–1238]
0.13
0.17
0.13
865 (770, 961)
1005 (887, 1123)
0.09
0.19
0.11
sTNF-RII
3989 [3153–5187]
4217 [3670–5172]
0.34
0.24
0.04*
4292 (3899, 4685)
4324 (3841, 4807)
0.92
0.20
0.08
sCD40L
2411 [1693–4456]
3769 [2492–6027]
0.01*
0.35
<0.01*
3171 (2311, 4031)
4551 (3493, 5608)
0.06
0.30
<0.01*
MCP-1
194 [144–216]
330 330-330]
0.14
0.39
0.05*
230 (96, 364)
724 (−299, 1746)
0.34
0.13
0.51
IL-6
0.88 [0.46–1.29]
1.82 [1.82-1.82]
0.26
0.26
0.22
1.13 (0.70, 1.56)
3.50 (0.23, 6.77)
0.16
0.31
0.10
sTNF-RI
927 [769–1091]
1017 1017-1017]
0.57
0.25
0.23
976 (845, 1106)
917 (−79, 1914)
0.91
0.24
0.21
sTNF-RII
3978 [3181–4826]
4761 4761-4761]
0.49
0.46
0.02*
4198 (3654, 4741)
5562 (1419, 9704)
0.51
0.42
0.02*
sCD40L
2213 [1680–3109]
3264 3264-3264]
0.43
0.40
0.05*
2934 (1915, 3952)
403 (−7366, 8171)
0.52
0.36
0.05
COC users
MCP-1
153 [111–189]
203 [175–317]
0.04*
0.23
0.31
166 (101, 231)
233 (190, 276)
0.11
0.29
0.14
IL-6
0.45 [0.37–0.78]
0.76 [0.47–1.16]
0.05*
0.39
0.07
0.59 (0.09, 1.09)
0.97 (0.65, 1.29)
0.22
0.52
<0.01*
sTNF-RI
780 [667–954]
1087 [822–1324]
0.04*
0.25
0.25
869 (625, 1112)
1007 (850, 1163)
0.37
0.46
0.01*
sTNF-RII
4573 [3518–5399]
4180 [3652–4554]
0.91
−0.05
0.81
4339 (3516, 5162)
4236 (3708, 4764)
0.84
0.04
0.86
sCD40L
4674 [2375–5773]
5799 [3062–7385]
0.34
0.28
0.19
3417 (943, 5891)
6184 (4596, 7772)
0.08
0.16
0.40
CVC users
MCP-1
172 [166–235]
194 [122–230]
0.91
0.02
0.94
189 (132, 246)
190 (144, 236)
0.99
−0.02
0.94
IL-6
0.72 [0.55–1.38]
0.83 [0.53–1.28]
0.97
−0.25
0.39
1.11 (0.59, 1.62)
0.92 (0.51, 1.33)
0.57
0.14
0.55
sTNF-RI
616 [534–791]
805 [660–1040]
0.09
−0.03
0.91
696 (476, 916)
854 (678, 1029)
0.27
0.37
0.12
sTNF-RII
3725 [2531–5640]
4940 [3754–5416]
0.39
0.03
0.91
4529 (3404, 5653)
4394 (3494, 5294)
0.85
0.40
0.09
sCD40L
2539 [1695–3582]
3101 [1737–3734]
0.73
−0.17
0.57
3528 (1846, 4671)
2642 (1512, 3772)
0.49
0.10
0.69
Note: a P value of <0.05 is indicated by *. Multivariate and partial Spearman correlation analyses adjusted for age, race, alcohol consumption, regular sleeping habit, and family history of CVD and stroke. There was only 1 subject in the nonusers group whose CRP ≥ 3.
